<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03141827</url>
  </required_header>
  <id_info>
    <org_study_id>LPNI-REB-15-9475</org_study_id>
    <nct_id>NCT03141827</nct_id>
  </id_info>
  <brief_title>The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production</brief_title>
  <acronym>LPNI</acronym>
  <official_title>The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the effect of insulin given as a nasal spray with a placebo. Insulin is a
      chemical messenger (hormone) in the body that controls fat (triglyceride) levels in the blood
      by controlling the amount of fat made by the liver and gut. Recent research suggests that
      insulin may work through the brain. The investigators hypothesize that preferential delivery
      of insulin into the brain, through nasal spray of the hormone, may affect the amount of fats
      made by the liver and gut.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each subject will be studied twice 4-6 weeks apart in random order in this single blinded
      study. In study A they will receive a single dose of insulin 40 IU through nasal spray. In
      study B they will receive placebo. On the day of the study subjects will drink regular liquid
      nutrient formula to maintain a constant fed state. A pancreatic clamp (octreotide with
      replacement glucose, insulin and growth hormone) will be started at 7am. From 9am a regular
      infusion of a stable isotope tracer will be started together with nasal spray of either
      insulin/placebo. Regular blood samples will be drawn to assess lipoprotein kinetics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2016</start_date>
  <completion_date type="Actual">April 26, 2017</completion_date>
  <primary_completion_date type="Actual">February 15, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Triglyceride-rich lipoprotein apolipoprotein B100 production rate</measure>
    <time_frame>10 hours</time_frame>
    <description>Triglyceride-rich lipoprotein apolipoprotein B100 production rate will be measured following nasal spray of insulin or placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Triglyceride-rich lipoprotein apolipoprotein B48 production rate</measure>
    <time_frame>10 hours</time_frame>
    <description>Triglyceride-rich lipoprotein apolipoprotein B48 production rate will be measured following nasal spray of insulin or placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal spray, insulin 40 IU, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nasal spray, placebo, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin 40 IU, nasal spray, single dose</description>
    <arm_group_label>Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, nasal spray, single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, aged 18 to 60 years

          2. Body mass index 20 to 40 kg/m2

          3. Hemoglobin in the normal range.

          4. Normal glucose tolerance in response to a 75g, 2-hr oral glucose tolerance test

          5. Women of reproductive age should be on contraception (oral contraceptive pill or
             intra-uterine device/coil) for at least 2 months prior to and after the study.

        Exclusion Criteria:

          1. Study participant with a history of hepatitis/hepatic disease that has been active
             within the previous two years.

          2. Any current or previous history of biliary disease (including gall stones, biliary
             atresia and cholecystitis) or pancreatitis.

          3. Any current or previous history of endocrine disease, dyslipidemia or malignancy

          4. Any significant active (over the past 12 months) disease of the gastrointestinal,
             pulmonary, neurological, renal (creatinine &gt; 1.5 mg/dL) genitourinary, hematological
             systems, or has severe uncontrolled treated or untreated hyper/ hypotension (sitting
             diastolic pressure &gt; 100 or systolic &gt; 180 or systolic pressure &lt;100) or proliferative
             retinopathy

          5. Use of immunosuppressive agents at any time during the study

          6. Allergy to any study medication

          7. Pregnancy or breastfeeding

          8. Heavy smoker

          9. Fasting blood glucose &gt; 6.0 mmol/l or known diabetes.

         10. Any history of a myocardial infarction or clinically significant, active,
             cardiovascular history including a history of arrhythmia's or conduction delays on
             electrocardiogram, unstable angina, or decompensated heart failure.

         11. Any nasal pathology.

         12. Any laboratory values: aspartate aminotransferase &gt; 2x upper limit of normal ; alanine
             aminotransferase &gt; 2x upper limit of normal; thyroid-stimulating hormone &gt; 6 milliunit
             per litre
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary F Lewis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tornto General Hospital, UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipoprotein</keyword>
  <keyword>Apolipoprotein</keyword>
  <keyword>Pancreatic clamp</keyword>
  <keyword>Insulin</keyword>
  <keyword>Nasal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

